News
NONOF
38.79
NaN%
--
Novo Nordisk: After A 70+% Drop, It's A Great Investment
Seeking Alpha · 16h ago
Lilly says Zepbound at higher doses tops Novo’s Wegovy HD
Seeking Alpha · 18h ago
Weekly Report: what happened at NONOF last week (0921-0925)?
Weekly Report · 1d ago
InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair
Seeking Alpha · 4d ago
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Seeking Alpha · 5d ago
Novo Nordisk: A Cheap Multiple Can't Fix Poor Growth
Seeking Alpha · 6d ago
Novo CEO says Ozempic maker is open to direct U.S. listing: FT
Seeking Alpha · 6d ago
Novo eyes hair-loss market as Ozempic maker looks to diversify
Seeking Alpha · 09/22 14:44
Weekly Report: what happened at NONOF last week (0914-0918)?
Weekly Report · 09/21 09:46
Under-Valued Dividend Growers: 8 Stocks Averaging A 10.2x P/E
Seeking Alpha · 09/19 13:00
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation
Seeking Alpha · 09/18 19:02
Sandoz wins Canada nod for generic Ozempic; inks licensing deal for generic Hemlibra
Seeking Alpha · 09/18 12:24
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval
Seeking Alpha · 09/17 15:42
Novo hemophilia therapy granted EU recommendation
Seeking Alpha · 09/17 14:52
Novo and Orbis ink drug discovery deal worth up to $1.4B
Seeking Alpha · 09/17 11:28
Novo Nordisk: Why This Corporate Rebrand Is More Than Simply PR Posturing
Seeking Alpha · 09/16 19:33
Novo teams up with Anthropic to speed up drug discovery
Seeking Alpha · 09/16 12:49
Novo CEO seeks a more consumer-centric culture from employees
Seeking Alpha · 09/15 18:23
Weekly Report: what happened at NONOF last week (0907-0911)?
Weekly Report · 09/14 09:49
S&P Futures Climb as Oil Retreats Ahead of Key U.S. Inflation Data; Oracle Jumps After Earnings
Barchart · 09/11 05:23
More
Webull provides a variety of real-time NONOF stock news. You can receive the latest news about Novo-Nordisk A S through multiple platforms. This information may help you make smarter investment decisions.
About NONOF
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.